Search Result

Results for "

secondary bile acids

" in MedChemExpress (MCE) Product Catalog:

By Targets:	G protein-coupled Bile Acid Receptor 1 (3) Acetyl-CoA Carboxylase (2) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (1) Autophagy (1) Bacterial (1) Drug Derivative (1) Endogenous Metabolite (8) FXR (6) Isotope-Labeled Compounds (2) Reference Standards (3)
By Research Areas:	Cancer (3) Infection (4) Inflammation/Immunology (3) Metabolic Disease (11)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter ELOVL G protein-coupled Bile Acid Receptor 1 Branched Chain Amino Acid Transaminase (BCAT)

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 26 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-13771A

Ursodeoxycholic acid sodium Maximum Cited Publications 26 Publications Verification Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-B0172S

Lithocholic acid-d4 1 Publications Verification 3α-Hydroxy-5β-cholanic acid-d₄	Isotope-Labeled Compounds Autophagy Apoptosis	Metabolic Disease
Lithocholic acid-d₄ is the deuterium labeled Lithocholic acid, which is a toxic secondary bile acid .

HY-48814

3-Epideoxycholic acid	Bacterial FXR	Infection Inflammation/Immunology
3-Epideoxycholic acid is a secondary bile acid and a microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR in dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exerts anti-inflammatory activity. 3-Epideoxycholic acid can promote the growth of the bacterium Bacteroides. 3-Epideoxycholic acid can be used in research related to inflammatory and immune diseases as well as bacterial infections .

HY-W399297

Isodeoxycholic acid 1 Publications Verification 7α,12α-Dihydroxycholanoic acid	Endogenous Metabolite	Metabolic Disease
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .

HY-116374A

Glycolithocholic acid sodium 2 Publications Verification Lithocholylglycine sodium	Endogenous Metabolite	Metabolic Disease
Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W585922

3β-Cholic acid	Drug Derivative	Others
3β-Cholic acid is a derivative of cholic acid (HY-N0324), and can be found in human feces .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-116374S

Glycolithocholic acid-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-W399297R

Isodeoxycholic acid (Standard) 7α,12α-Dihydroxycholanoic acid (Standard)	Endogenous Metabolite Reference Standards	Infection Metabolic Disease
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) Standard is the analytical standard of Isodeoxycholic acid (HY-W399297). This product is intended for research and analytical applications. Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .

HY-N11602

Deoxycholic acid 3-sulfate	Endogenous Metabolite	Metabolic Disease
Deoxycholic acid 3-sulfate is a sulfated metabolite of deoxycholic acid, belonging to the sulfate ester form of secondary bile acids. The proportion of Deoxycholic acid 3-sulfate in serum from both healthy states and cholestatic states is below the limit of detection .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 26 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Human Gut Microbiota Metabolites Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-13771A

Ursodeoxycholic acid sodium Maximum Cited Publications 26 Publications Verification Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Microorganisms Classification of Application Fields Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-W399297

Isodeoxycholic acid 1 Publications Verification 7α,12α-Dihydroxycholanoic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Disease markers Endogenous metabolite Steroids Source Classification	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-W399297R

Isodeoxycholic acid (Standard) 7α,12α-Dihydroxycholanoic acid (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Endogenous Metabolite Reference Standards
Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) Standard is the analytical standard of Isodeoxycholic acid (HY-W399297). This product is intended for research and analytical applications. Isodeoxycholic acid (7α,12α-Dihydroxycholanoic acid) is a 3β-hydroxylated secondary bile acid. Isodeoxycholic acid is produced by epimerization of deoxycholic acid by intestinal bacteria. Isodeoxycholic acid is detectable in feces, mainly existing as saponifiable conjugates with long-chain fatty acids. Isodeoxycholic acid participates in the regulation of intestinal physiology .

HY-N11602

Deoxycholic acid 3-sulfate	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	Endogenous Metabolite
Deoxycholic acid 3-sulfate is a sulfated metabolite of deoxycholic acid, belonging to the sulfate ester form of secondary bile acids. The proportion of Deoxycholic acid 3-sulfate in serum from both healthy states and cholestatic states is below the limit of detection .

Cat. No.	Nombre del producto	Chemical Structure

HY-B0172S

Lithocholic acid-d4 1 Publications Verification
Lithocholic acid-d₄ is the deuterium labeled Lithocholic acid, which is a toxic secondary bile acid .

HY-116374S

Glycolithocholic acid-d4
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

secondary bile acids

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products